14.72 USD
+0.16 (+1.1%)
Last: Feb 3, 2026, 11:41 AM
Overall HCM gets a fundamental rating of 5 out of 10. We evaluated HCM against 191 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of HCM get a neutral evaluation. Nothing too spectacular is happening here. HCM is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one!
1. Profitability
1.1 Basic Checks
- HCM had positive earnings in the past year.
- In the past year HCM has reported a negative cash flow from operations.
- In multiple years HCM reported negative net income over the last 5 years.
- The reported operating cash flow has been mixed in the past 5 years: HCM reported negative operating cash flow in multiple years.
1.2 Ratios
- HCM has a better Return On Assets (26.29%) than 98.95% of its industry peers.
- HCM has a better Return On Equity (37.99%) than 96.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- HCM has a better Profit Margin (77.53%) than 98.95% of its industry peers.
- HCM's Gross Margin of 44.15% is fine compared to the rest of the industry. HCM outperforms 63.35% of its industry peers.
- HCM's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
2. Health
2.1 Basic Checks
- HCM does not have a ROIC to compare to the WACC, probably because it is not profitable.
- HCM has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- An Altman-Z score of 3.59 indicates that HCM is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.59, HCM is in the better half of the industry, outperforming 68.06% of the companies in the same industry.
- A Debt/Equity ratio of 0.08 indicates that HCM is not too dependend on debt financing.
- HCM's Debt to Equity ratio of 0.08 is in line compared to the rest of the industry. HCM outperforms 51.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.59 |
ROIC/WACCN/A
WACC9.51%
2.3 Liquidity
- HCM has a Current Ratio of 4.65. This indicates that HCM is financially healthy and has no problem in meeting its short term obligations.
- With a decent Current ratio value of 4.65, HCM is doing good in the industry, outperforming 63.35% of the companies in the same industry.
- A Quick Ratio of 4.51 indicates that HCM has no problem at all paying its short term obligations.
- HCM has a Quick ratio of 4.51. This is in the better half of the industry: HCM outperforms 64.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 |
3. Growth
3.1 Past
- HCM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 1172.34%, which is quite impressive.
- Looking at the last year, HCM shows a decrease in Revenue. The Revenue has decreased by -1.41% in the last year.
- The Revenue has been growing by 25.20% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
3.2 Future
- HCM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 52.63% yearly.
- Based on estimates for the next years, HCM will show a very strong growth in Revenue. The Revenue will grow by 20.25% on average per year.
EPS Next Y892.54%
EPS Next 2Y81.46%
EPS Next 3Y57.39%
EPS Next 5Y52.63%
Revenue Next Year-11.82%
Revenue Next 2Y0.94%
Revenue Next 3Y5.99%
Revenue Next 5Y20.25%
3.3 Evolution
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- Based on the Price/Earnings ratio of 5.41, the valuation of HCM can be described as very cheap.
- Based on the Price/Earnings ratio, HCM is valued cheaper than 95.81% of the companies in the same industry.
- HCM is valuated cheaply when we compare the Price/Earnings ratio to 28.41, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 35.18, which means the current valuation is very expensive for HCM.
- 72.25% of the companies in the same industry are more expensive than HCM, based on the Price/Forward Earnings ratio.
- HCM's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 25.64.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.41 | ||
| Fwd PE | 35.18 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- A more expensive valuation may be justified as HCM's earnings are expected to grow with 57.39% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y81.46%
EPS Next 3Y57.39%
5. Dividend
5.1 Amount
- No dividends for HCM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:HCM (2/3/2026, 11:41:54 AM)
14.72
+0.16 (+1.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners19.06%
Inst Owner Change-2.08%
Ins Owners0.58%
Ins Owner ChangeN/A
Market Cap2.53B
Revenue(TTM)602.20M
Net Income(TTM)466.88M
Analysts83.7
Price Target15.41 (4.69%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-5.22%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-1.03%
EPS NY rev (3m)-0.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.04%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.41 | ||
| Fwd PE | 35.18 | ||
| P/S | 4.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.06 | ||
| P/tB | 2.06 | ||
| EV/EBITDA | N/A |
EPS(TTM)2.72
EY18.48%
EPS(NY)0.42
Fwd EY2.84%
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS3.5
BVpS7.15
TBVpS7.15
PEG (NY)0.01
PEG (5Y)N/A
Graham Number20.92
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 26.29% | ||
| ROE | 37.99% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | 77.53% | ||
| GM | 44.15% | ||
| FCFM | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y17.54%
GM growth 5Y15.38%
F-Score5
Asset Turnover0.34
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.08 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 221.94% | ||
| Cap/Sales | 4.5% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.65 | ||
| Quick Ratio | 4.51 | ||
| Altman-Z | 3.59 |
F-Score5
WACC9.51%
ROIC/WACCN/A
Cap/Depr(3y)321.95%
Cap/Depr(5y)304.39%
Cap/Sales(3y)5.11%
Cap/Sales(5y)5.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1172.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1661.49%
EPS Next Y892.54%
EPS Next 2Y81.46%
EPS Next 3Y57.39%
EPS Next 5Y52.63%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y20.96%
Revenue growth 5Y25.2%
Sales Q2Q%-9.16%
Revenue Next Year-11.82%
Revenue Next 2Y0.94%
Revenue Next 3Y5.99%
Revenue Next 5Y20.25%
EBIT growth 1Y83.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year81.15%
EBIT Next 3Y46.12%
EBIT Next 5Y43.18%
FCF growth 1Y-2591.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-168.32%
OCF growth 3YN/A
OCF growth 5YN/A
HUTCHMED CHINA-ADR / HCM FAQ
Can you provide the ChartMill fundamental rating for HUTCHMED CHINA-ADR?
ChartMill assigns a fundamental rating of 5 / 10 to HCM.
Can you provide the valuation status for HUTCHMED CHINA-ADR?
ChartMill assigns a valuation rating of 5 / 10 to HUTCHMED CHINA-ADR (HCM). This can be considered as Fairly Valued.
Can you provide the profitability details for HUTCHMED CHINA-ADR?
HUTCHMED CHINA-ADR (HCM) has a profitability rating of 4 / 10.
What are the PE and PB ratios of HUTCHMED CHINA-ADR (HCM) stock?
The Price/Earnings (PE) ratio for HUTCHMED CHINA-ADR (HCM) is 5.41 and the Price/Book (PB) ratio is 2.06.
Can you provide the expected EPS growth for HCM stock?
The Earnings per Share (EPS) of HUTCHMED CHINA-ADR (HCM) is expected to grow by 892.54% in the next year.